Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,409 | 313 | 2,060 |
| Samples | 533 | 112 | 412 |
| Peptides | 401 | 87 | 338 |
Function
MSR1 · Macrophage scavenger receptor 1
This gene encodes the class A macrophage scavenger receptors, which include three different types (1, 2, 3) generated by alternative splicing of this gene. These receptors or isoforms are macrophage-specific trimeric integral membrane glycoproteins and have been implicated in many macrophage-associated physiological and pathological processes including atherosclerosis, Alzheimer's disease, and host defense. The isoforms type 1 and type 2 are functional receptors and are able to mediate the endocytosis of modified low density lipoproteins (LDLs). The isoform type 3 does not internalize modified LDL (acetyl-LDL) despite having the domain shown to mediate this function in the types 1 and 2 isoforms. It has an altered intracellular processing and is trapped within the endoplasmic reticulum, making it unable to perform endocytosis. The isoform type 3 can inhibit the function of isoforms type 1 and type 2 when co-expressed, indicating a dominant negative effect and suggesting a mechanism for regulation of scavenger receptor activity in macrophages. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 356 amino-acid changes on canonical ENST00000262101 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MSR1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MSR1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 10/98 10% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 13/210 6% | 114/1899 6% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Other Solid Cancers | 3/94 3% | 41/1515 3% |
| Endometrial Carcinoma | 1/42 2% | 16/612 3% |
| Neuroendocrine Tumour | 9/154 6% | 9/577 2% |
| Gastric Carcinoma | 0/74 0% | 44/1809 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 16/810 2% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 17/1390 1% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Colorectal Carcinoma | 12/143 8% | 42/3239 1% |
| Rhabdomyosarcoma | 2/33 6% | 1/171 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Burkitts Lymphoma | 2/32 6% | 1/196 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Esophageal Carcinoma | 0/23 0% | 10/769 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Head and Neck Carcinoma | 3/85 4% | 15/1574 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Plasma Cell Myeloma | 1/44 2% | 2/305 1% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Glioma | 0/52 0% | 13/2127 1% |
| Ovarian Carcinoma | 1/109 1% | 5/998 0% |
Mutation Distribution
Where MSR1 is mutated · all tissues, split by cell line vs tissue
How many mutations in MSR1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,409 mutations in MSR1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|